RU2005134394A - Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа - Google Patents
Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа Download PDFInfo
- Publication number
- RU2005134394A RU2005134394A RU2005134394/14A RU2005134394A RU2005134394A RU 2005134394 A RU2005134394 A RU 2005134394A RU 2005134394/14 A RU2005134394/14 A RU 2005134394/14A RU 2005134394 A RU2005134394 A RU 2005134394A RU 2005134394 A RU2005134394 A RU 2005134394A
- Authority
- RU
- Russia
- Prior art keywords
- syndrome
- thyroid
- disease
- autoimmune
- antibody
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2887—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A61P31/06—Antibacterial agents for tuberculosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
Claims (13)
1. Способ лечения аутоиммунного заболевания у млекопитающего с неадекватным ответом на ингибитор TNFα, заключающийся во введении такому млекопитающему терапевтически эффективного количества антагониста, который связывается с поверхностным маркером В-клеток.
2. Способ по п.1, в котором поверхностный маркер В-клеток выбран из группы, включающей: CD10, CD19, CD20, CD21, CD22, CD23, CD24, CD37, CD40, CD53, CD72, CD73, CD74, CDw75, CDw76, CD77, CDw78, CD79a, CD80, CD81, CD82, CD83, CDw84, CD85 и CD86.
3. Способ по п.1, в котором антагонистом является антитело.
4. Способ по п.3, в котором антитело связывает CD20.
5. Способ по п.1, в котором аутоиммунное заболевание выбрано из группы, включающей артрит, ревматоидный артрит, ювенильный ревматоидный артрит, остеоартрит, псориатический артрит, псориаз, дерматит, полимиозит/дерматомиозит, токсический эпидермальный некролиз, системная склеродермия и склероз, иммунные ответы, связанные с воспалительными заболеваниями кишечника, болезнь Крона, язвенный колит, респираторный дистресс-синдром, респираторный дистресс-синдром взрослых (ARDS), менингит, энцефалит, увеит, колит, гломерулонефрит, аллергические состояния, экзема, астма, состояния, сопровождающиеся Т-клеточной инфильтрацией и хроническим воспалительным ответом, атеросклероз, аутоиммунный миокардит, нарушение адгезии лейкоцитов, системная красная волчанка (SLE), ювенильный диабет, рассеянный склероз, аллергический энцефаломиелит, иммунные ответы, связанные с реакцией гиперчувствительности немедленного и замедленного типов, опосредованной цитокинами и Т-лимфоцитами, туберкулез, саркоидоз, гарнулематоз, включая гранулематоз Вегенера, агранулоцитоз, васкулит (включая ANCA), апластическая анемия, анемия Дайемонда-Блекфэна, иммунная гемолитическая анемия, включая аутоиммунную гемолитическую анемию (AIHA), пернициозная анемия, истинная эритроцитарная аплазия (PRCA), недостаточность фактора VIII, гемофилия А, аутоиммунная нейтропения, панцитопения, лейкопения, заболевания, ассоциированные с диапедезом лейкоцитов, воспалительные заболевания центральной нервной системы (CNS), синдром множественного поражения органов, миастения гравис, заболевания, опосредованные комплексом антиген-антитело, заболевания, связанные с образованием антигломерулярных антител в базальной мембране, антифосфолипидный синдром, аллергический нейрит, болезнь Бехчета, синдром Кастельмана, синдром Гудпасчера, миастенический синдром Ламберта-Итона, Синдром Рейно, синдром Шегрена, синдром Стивенса-Джонсона, реакция отторжения трансплантата, реакция "трансплантат против хозяина" (GVHD), пузырчатка буллезная, пузырчатка, аутоиммунные полиэндокринопатии, синдром Рейтера, синдром "деревянного человека", гигантоклеточный артериит, иммунокомплексный нефрит, IgA нефропатия, IgM полинейропатии или опосредованные IgM нейропатии, идиопатическая тромбоцитопеническая пурпура (ITP), тромботическая тромбоцитопеническая пурпура (ТТР), аутоиммунная тромбоцитопения, аутоиммунные заболевания яичек и яичников, включая аутоиммунный орхит и оофорит, первичный гипотиреоидизм, аутоиммунные эндокринные заболевания, включая аутоиммунный тиреоидит, хронический тиреоидит (тиреоидит Хашимото), подострый тиреоидит, идиопатический гипотиреоидизм, болезнь Аддисона, болезнь Грейвса, аутоиммунный полигландулярный синдром (или синдромы полигландулярной эндокринопатии), диабет I типа, также называемый инсулинзависимым сахарным диабетом (IDDM) и синдром Шихана; аутоиммунный гепатит, лимфоидный интерстициальный пневмонит (HIV), облитерирующий бронхиолит (нетрансплантационный) в противоположность NSIP, синдром Гиейна-Барре, васкулиты крупных сосудов (включая ревматическую полимиалгию и гигантоклеточный артериит (болезнь Такаясу), васкулиты сосудов среднего диаметра (включая болезнь Кавасаки и узелковый полиартериит), анкилозирующий спондилит, болезнь Бергера (IgA нефропатия), быстро прогрессирущий гломерулонефрит, первичный билиарный цирроз, целиакия (глютеновая энтеропатия), криоглобулинемия, боковой амиотрофический склероз (ALS), ишемическая болезнь сердца.
6. Способ по п.1, в котором млекопитающим является человек.
7. Способ по п.3, в котором антитело не конъюгировано с цитотоксическим агентом.
8. Способ по п.4, в котором антителом является ритуксимаб.
9. Способ по п.4, в котором антителом является гумманизированным атителом 2Н7 v16, содержащим вариабельные домены, представленные SEQ ID Nos. 1 и 2.
10. Способ по п.3, в котором антитело конъюгировано с цитотоксическим агентом.
11. Способ по п.1, который, по существу, заключается во введении млекопитающему антагониста.
12. Способ лечения ревматоидного артрита у млекопитающего с неадекватным ответом на ингибитор TNFα, заключающийся во введении такому млекопитающему терапевтически эффективного количества антитела, которое связывается с CD20.
13. Способ снижения риска негативных побочных эффектов, таких как инфекция, сердечная недостаточность и демиелинизация, заключающийся во введении млекопитающему, страдающему аутоиммунным заболеванием, терапевтически эффективного количества антагониста, который связывается с поверхностным маркером В-клеток.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US46148103P | 2003-04-09 | 2003-04-09 | |
US60/461,481 | 2003-04-09 | ||
PCT/US2004/010509 WO2004091657A2 (en) | 2003-04-09 | 2004-04-06 | Therapy of autoimmune disease in a patient with an inadequate response to a tnf-alpha inhibitor |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2008140661/15A Division RU2489166C2 (ru) | 2006-04-09 | 2008-10-14 | Применение антитела для лечения аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа |
Publications (3)
Publication Number | Publication Date |
---|---|
RU2005134394A true RU2005134394A (ru) | 2006-05-27 |
RU2358762C2 RU2358762C2 (ru) | 2009-06-20 |
RU2358762C9 RU2358762C9 (ru) | 2016-10-10 |
Family
ID=33299824
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2005134394/14A RU2358762C9 (ru) | 2003-04-09 | 2004-04-06 | Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа |
Country Status (32)
Country | Link |
---|---|
US (4) | US20040202658A1 (ru) |
EP (2) | EP2062916A3 (ru) |
JP (3) | JP2006522811A (ru) |
KR (2) | KR20110044809A (ru) |
CN (2) | CN101371924A (ru) |
AT (1) | ATE425766T1 (ru) |
AU (1) | AU2004229376B2 (ru) |
BR (1) | BRPI0409534A (ru) |
CA (1) | CA2519870A1 (ru) |
CR (1) | CR8033A (ru) |
CY (1) | CY1109127T1 (ru) |
DE (1) | DE602004020061D1 (ru) |
DK (1) | DK1613350T3 (ru) |
EC (1) | ECSP056082A (ru) |
ES (1) | ES2322267T3 (ru) |
HK (1) | HK1086480A1 (ru) |
HR (2) | HRP20050940A2 (ru) |
IL (2) | IL171038A (ru) |
MA (1) | MA27838A1 (ru) |
ME (1) | ME00426B (ru) |
MX (1) | MXPA05010778A (ru) |
NO (1) | NO20055253L (ru) |
NZ (2) | NZ587776A (ru) |
PL (1) | PL1613350T3 (ru) |
PT (1) | PT1613350E (ru) |
RS (1) | RS51686B (ru) |
RU (1) | RU2358762C9 (ru) |
SI (1) | SI1613350T1 (ru) |
TN (1) | TNSN05234A1 (ru) |
UA (2) | UA91961C2 (ru) |
WO (1) | WO2004091657A2 (ru) |
ZA (1) | ZA200507805B (ru) |
Families Citing this family (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000067796A1 (en) | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
JP2003528805A (ja) * | 1999-07-12 | 2003-09-30 | ジェネンテック・インコーポレーテッド | Cd20に結合するアンタゴニストを用いた異種抗原に対する免疫応答のブロッキング |
JP2005526501A (ja) | 2002-02-21 | 2005-09-08 | デューク・ユニヴァーシティ | 自己免疫疾患用の試薬および治療方法 |
US20090217404A1 (en) * | 2002-09-27 | 2009-08-27 | Lowe Scott W | Cell-based RNA interference and related methods and compositions |
DE60332957D1 (de) * | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
DK1599573T3 (da) * | 2003-02-17 | 2013-07-08 | Cold Spring Harbor Lab | Model til at studere genernes rolle i tumorresistens over for kemoterapi |
US20090186839A1 (en) * | 2003-02-17 | 2009-07-23 | Cold Spring Harbor Laboratory | Model for studying the role of genes in chemoresistance |
EP1460088A1 (en) | 2003-03-21 | 2004-09-22 | Biotest AG | Humanized anti-CD4 antibody with immunosuppressive properties |
ES2322267T3 (es) | 2003-04-09 | 2009-06-18 | Genentech, Inc. | Terapia de una enfermedad autoinmunologica en un paciente que presenta una respuesta inadecuada a un inhibidor de tnf-alfa. |
WO2005000901A2 (en) * | 2003-05-09 | 2005-01-06 | Duke University | Cd20-specific antibodies and methods of employing same |
AR044388A1 (es) * | 2003-05-20 | 2005-09-07 | Applied Molecular Evolution | Moleculas de union a cd20 |
MXPA06002134A (es) * | 2003-08-29 | 2006-05-31 | Genentech Inc | Terapia de trastornos oculares. |
EA036531B1 (ru) | 2003-11-05 | 2020-11-19 | Роше Гликарт Аг | Гуманизированное антитело типа ii к cd20 (варианты), фармацевтическая композиция, содержащая эти варианты антитела, и их применение |
RU2006140374A (ru) * | 2004-04-16 | 2008-05-27 | Дженентек, Инк. (Us) | Лечение нарушений |
US20060051345A1 (en) * | 2004-06-04 | 2006-03-09 | Genentech, Inc. | Method for treating multiple sclerosis |
AR049292A1 (es) * | 2004-06-04 | 2006-07-12 | Genentech Inc | Metodo para tratar lupus con un anticuerpo cd20 |
BRPI0513100A (pt) * | 2004-07-22 | 2007-10-23 | Genentech Inc | métodos de tratamento da sìndrome de sjÍgren e artigos manufaturados |
EA012464B1 (ru) | 2004-08-04 | 2009-10-30 | Эпплайд Молекьюлар Эволюшн, Инк. | Антитело против cd20 и его применение |
WO2006041680A2 (en) * | 2004-10-05 | 2006-04-20 | Genentech, Inc. | Method for treating vasculitis |
US8137907B2 (en) * | 2005-01-03 | 2012-03-20 | Cold Spring Harbor Laboratory | Orthotopic and genetically tractable non-human animal model for liver cancer and the uses thereof |
GT200600020A (es) * | 2005-01-13 | 2006-11-08 | Procedimiento de tratamiento | |
US20060233791A1 (en) * | 2005-02-15 | 2006-10-19 | Duke University | Anti-CD19 antibodies and uses in oncology |
US8444973B2 (en) * | 2005-02-15 | 2013-05-21 | Duke University | Anti-CD19 antibodies and uses in B cell disorders |
SG10201912554TA (en) * | 2005-03-23 | 2020-02-27 | Genmab As | Antibodies against cd38 for treatment of multiple myeloma |
AR053579A1 (es) * | 2005-04-15 | 2007-05-09 | Genentech Inc | Tratamiento de la enfermedad inflamatoria intestinal (eii) |
EP1885755A4 (en) * | 2005-05-05 | 2009-07-29 | Univ Duke | TREATMENTS OF AUTOIMMUNE DISEASES BY ANTI-CD19 ANTIBODIES |
JP2008545958A (ja) * | 2005-05-20 | 2008-12-18 | ジェネンテック・インコーポレーテッド | 自己免疫性疾患の被検体の生体試料の前処理 |
WO2007053184A2 (en) | 2005-05-31 | 2007-05-10 | Cold Spring Harbor Laboratory | Methods for producing micrornas |
WO2006133450A2 (en) * | 2005-06-08 | 2006-12-14 | Duke University | Anti-cd19 antibody therapy for the transplantation |
EP2468881A3 (en) * | 2005-07-21 | 2012-08-15 | Abbott Laboratories | Multiple gene expression including sorf contructs and methods with polyproteins, pro-proteins, and proteolysis |
US8470318B2 (en) * | 2005-11-07 | 2013-06-25 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
MY149159A (en) * | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
EP2540741A1 (en) | 2006-03-06 | 2013-01-02 | Aeres Biomedical Limited | Humanized anti-CD22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
WO2007103470A2 (en) * | 2006-03-06 | 2007-09-13 | Medimmune, Inc. | Humanized anti-cd22 antibodies and their use in treatment of oncology, transplantation and autoimmune disease |
EP2815768A3 (en) * | 2006-04-05 | 2015-01-14 | The Rockefeller University | Polypeptides with enhanced anti-inflammatory and decreased cytotoxic properties and relating methods |
US8768629B2 (en) * | 2009-02-11 | 2014-07-01 | Caris Mpi, Inc. | Molecular profiling of tumors |
IL282783B2 (en) | 2006-05-18 | 2023-09-01 | Caris Mpi Inc | A system and method for determining a personalized medical intervention for a disease stage |
MX2009002414A (es) | 2006-09-08 | 2009-05-20 | Medimmune Llc | Anticuerpos anti-cd19 humanizados y su uso en el tratamiento de oncologia, transplante y enfermedad autoinmunitaria. |
US8420330B2 (en) | 2011-07-15 | 2013-04-16 | Myra A. Lipes | Diagnosis and treatment of cardiac troponin 1 (cTn1) autoantibody-mediated heart disease |
GB0707208D0 (en) * | 2007-04-13 | 2007-05-23 | Istituto Superiore Di Sanito | Novel disease treatments |
EP2174667B1 (en) * | 2007-07-26 | 2017-01-04 | Osaka University | Agent for treatment of ophthalmia containing interleukin-6 receptor inhibitor as active ingredient |
HUE031533T2 (hu) * | 2007-10-19 | 2017-07-28 | Seattle Genetics Inc | CD19-kötõszerek valamint alkalmazásuk |
WO2009121690A1 (en) * | 2008-03-13 | 2009-10-08 | Biotest Ag | Agent for treating disease |
MX2010010026A (es) * | 2008-03-13 | 2011-03-21 | Biotest Ag | Agente para tratar enfermedad. |
SG190627A1 (en) * | 2008-03-13 | 2013-06-28 | Biotest Ag | Agent for treating disease |
TW201014605A (en) | 2008-09-16 | 2010-04-16 | Genentech Inc | Methods for treating progressive multiple sclerosis |
SG194362A1 (en) * | 2008-09-29 | 2013-11-29 | Biotest Ag | Composition for treating disease |
CN106153918A (zh) * | 2008-10-14 | 2016-11-23 | 卡里斯Mpi公司 | 描绘肿瘤类型生物标志模式和特征集的基因靶和基因表达的蛋白靶 |
WO2010054288A2 (en) * | 2008-11-07 | 2010-05-14 | National Jewish Health | Diagnosis and treatment of autoimmune diseases by targeting autoimmune-related b cells ("abcs") |
WO2010056337A2 (en) * | 2008-11-12 | 2010-05-20 | Caris Mpi, Inc. | Methods and systems of using exosomes for determining phenotypes |
JP2012509270A (ja) * | 2008-11-17 | 2012-04-19 | ジェネンテック, インコーポレイテッド | 生理的条件下での高分子の凝集を低減するための方法及び製剤 |
PE20120169A1 (es) * | 2008-11-17 | 2012-02-29 | Genentech Inc | Metodo y formulacion para reducir la agregacion de una macromolecula bajo condiciones fisiologicas |
WO2010075249A2 (en) | 2008-12-22 | 2010-07-01 | Genentech, Inc. | A method for treating rheumatoid arthritis with b-cell antagonists |
EP2373339B1 (en) * | 2009-01-06 | 2017-04-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | A b cell depleting agent for the treatment of atherosclerosis |
JP5246709B2 (ja) * | 2009-06-09 | 2013-07-24 | 独立行政法人医薬基盤研究所 | 自己免疫疾患検査用バイオマーカー及び検査方法 |
WO2011011706A2 (en) * | 2009-07-24 | 2011-01-27 | The Johns Hopkins University | Methods and compositions for treating or preventing autoimmune diseases using immunomodulatory agents |
AR078161A1 (es) | 2009-09-11 | 2011-10-19 | Hoffmann La Roche | Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento. |
US9260517B2 (en) | 2009-11-17 | 2016-02-16 | Musc Foundation For Research Development | Human monoclonal antibodies to human nucleolin |
GB0920944D0 (en) | 2009-11-30 | 2010-01-13 | Biotest Ag | Agents for treating disease |
JO3417B1 (ar) | 2010-01-08 | 2019-10-20 | Regeneron Pharma | الصيغ المستقرة التي تحتوي على الأجسام المضادة لمضاد مستقبل( interleukin-6 (il-6r |
CN102933231B (zh) | 2010-02-10 | 2015-07-29 | 伊缪诺金公司 | Cd20抗体及其用途 |
JP5808349B2 (ja) | 2010-03-01 | 2015-11-10 | カリス ライフ サイエンシズ スウィッツァーランド ホールディングスゲーエムベーハー | セラノーシスのためのバイオマーカー |
BR112012025593A2 (pt) | 2010-04-06 | 2019-06-25 | Caris Life Sciences Luxembourg Holdings | biomarcadores em circulação para doença |
NZ603196A (en) * | 2010-04-28 | 2014-07-25 | Oncolmmune Inc | Methods of use of soluble cd24 for therapy of rheumatoid arthritis |
WO2011156740A2 (en) * | 2010-06-10 | 2011-12-15 | Myra Lipes | Diagnosis of myocardial autoimmunity in heart disease |
EP3578205A1 (en) | 2010-08-06 | 2019-12-11 | ModernaTX, Inc. | A pharmaceutical formulation comprising engineered nucleic acids and medical use thereof |
US20120237975A1 (en) | 2010-10-01 | 2012-09-20 | Jason Schrum | Engineered nucleic acids and methods of use thereof |
EP2691101A2 (en) | 2011-03-31 | 2014-02-05 | Moderna Therapeutics, Inc. | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
CA2850624A1 (en) | 2011-10-03 | 2013-04-11 | Moderna Therapeutics, Inc. | Modified nucleosides, nucleotides, and nucleic acids, and uses thereof |
TWI589299B (zh) * | 2011-10-11 | 2017-07-01 | 再生元醫藥公司 | 用於治療類風濕性關節炎之組成物及其使用方法 |
US9943594B2 (en) | 2011-10-11 | 2018-04-17 | Sanofi Biotechnology | Methods for the treatment of rheumatoid arthritis |
KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
US9823246B2 (en) | 2011-12-28 | 2017-11-21 | The Board Of Trustees Of The Leland Stanford Junior University | Fluorescence enhancing plasmonic nanoscopic gold films and assays based thereon |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
CA2868398A1 (en) | 2012-04-02 | 2013-10-10 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US20140075585A1 (en) * | 2012-09-12 | 2014-03-13 | Futwan Al-Mohanna | Tetraspanin CD82 as a Diagnostic and/or Therapeutic Module for Xenograft Recognition and/or Rejection |
HU230680B1 (hu) * | 2012-10-19 | 2017-08-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Diagnosztikai eljárás |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
WO2015028662A1 (en) * | 2013-08-30 | 2015-03-05 | Consejo Superior De Investigaciones Cientificas (Csic) | Compositions and methods for characterization and amelioration of rheumatoid arthritis |
EP3052106A4 (en) | 2013-09-30 | 2017-07-19 | ModernaTX, Inc. | Polynucleotides encoding immune modulating polypeptides |
JP2016538829A (ja) | 2013-10-03 | 2016-12-15 | モデルナ セラピューティクス インコーポレイテッドModerna Therapeutics,Inc. | 低密度リポタンパク質受容体をコードするポリヌクレオチド |
WO2016073778A2 (en) | 2014-11-05 | 2016-05-12 | Nirmidas Biotech, Inc. | Metal composites for enhanced imaging |
AR104368A1 (es) | 2015-04-03 | 2017-07-19 | Lilly Co Eli | Anticuerpos biespecíficos anti-cd20- / anti-baff |
EP3397287A1 (en) | 2015-12-30 | 2018-11-07 | Genentech, Inc. | Formulations with reduced degradation of polysorbate |
IT201700110784A1 (it) * | 2017-10-03 | 2019-04-03 | Fidia Farm Spa | Composizioni farmaceutiche contenenti Acido Ialuronico e Carnosina e relativo uso |
EP3520803A1 (en) * | 2018-01-31 | 2019-08-07 | Zarodex Therapeutics Limited | Novel uses |
PE20211001A1 (es) | 2018-02-27 | 2021-06-01 | Incyte Corp | Imidazopirimidinas y triazolopirimidinas como inhibidores de a2a / a2b |
CR20200392A (es) | 2018-03-09 | 2020-11-17 | Agenus Inc | Anticuerpos anti-cd73 y métodos de uso de los mismos |
CN114470001A (zh) * | 2018-04-18 | 2022-05-13 | 浙江大学 | 人羊膜上皮细胞在自身免疫性疾病中的治疗用途 |
US10519227B2 (en) | 2018-05-08 | 2019-12-31 | Ten Peaks LLC | Methods for reducing drug-induced liver injury |
US11124566B2 (en) | 2018-05-08 | 2021-09-21 | Ten Peaks LLC | Methods for reducing drug-induced liver injury |
US11180547B2 (en) | 2018-05-08 | 2021-11-23 | Ten Peaks LLC | Methods for reducing drug-induced liver injury |
JP7391046B2 (ja) | 2018-05-18 | 2023-12-04 | インサイト・コーポレイション | A2a/a2b阻害剤としての縮合ピリミジン誘導体 |
CN112955222A (zh) | 2018-08-29 | 2021-06-11 | 里珍纳龙药品有限公司 | 用于治疗患有类风湿性关节炎的个体的方法和组合物 |
WO2020054979A1 (ko) * | 2018-09-12 | 2020-03-19 | 아주대학교산학협력단 | Cd83 억제제를 유효성분으로 포함하는 베체트병의 예방 또는 치료용 조성물 |
RU2724469C2 (ru) | 2018-10-31 | 2020-06-23 | Закрытое Акционерное Общество "Биокад" | Моноклональное антитело, которое специфически связывается с cd20 |
TWI829857B (zh) | 2019-01-29 | 2024-01-21 | 美商英塞特公司 | 作為a2a / a2b抑制劑之吡唑并吡啶及***并吡啶 |
CN114206442A (zh) | 2019-01-31 | 2022-03-18 | 赛诺菲生物技术公司 | 用于治疗幼年特发性关节炎的抗il-6受体抗体 |
EP4025605A1 (en) | 2019-09-06 | 2022-07-13 | Symphogen A/S | Anti-cd73 antibodies |
US20210230294A1 (en) | 2020-01-03 | 2021-07-29 | Incyte Corporation | Cd73 inhibitor and a2a/a2b adenosine receptor inhibitor combination therapy |
EP4014993A1 (en) * | 2020-12-21 | 2022-06-22 | Stichting Sint Maartenskliniek | Rituximab for treatment of polymyalgia rheumatica |
CA3207066A1 (en) | 2020-12-29 | 2022-07-07 | Incyte Corporation | Combination therapy comprising a2a/a2b inhibitors, pd-1/pd-l1 inhibitors, and anti-cd73 antibodies |
Family Cites Families (106)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
IL47062A (en) | 1975-04-10 | 1979-07-25 | Yeda Res & Dev | Process for diminishing antigenicity of tissues to be usedas transplants by treatment with glutaraldehyde |
US4665077A (en) | 1979-03-19 | 1987-05-12 | The Upjohn Company | Method for treating rejection of organ or skin grafts with 6-aryl pyrimidine compounds |
WO1981001145A1 (en) | 1979-10-18 | 1981-04-30 | Univ Illinois | Hydrolytic enzyme-activatible pro-drugs |
US4485045A (en) | 1981-07-06 | 1984-11-27 | Research Corporation | Synthetic phosphatidyl cholines useful in forming liposomes |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4544545A (en) | 1983-06-20 | 1985-10-01 | Trustees University Of Massachusetts | Liposomes containing modified cholesterol for organ targeting |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
US5567610A (en) | 1986-09-04 | 1996-10-22 | Bioinvent International Ab | Method of producing human monoclonal antibodies and kit therefor |
IL85035A0 (en) * | 1987-01-08 | 1988-06-30 | Int Genetic Eng | Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same |
GB8705477D0 (en) | 1987-03-09 | 1987-04-15 | Carlton Med Prod | Drug delivery systems |
US4975278A (en) | 1988-02-26 | 1990-12-04 | Bristol-Myers Company | Antibody-enzyme conjugates in combination with prodrugs for the delivery of cytotoxic agents to tumor cells |
CA1338518C (en) | 1987-09-23 | 1996-08-13 | Joyce M. Zarling | Antibody heteroconjugates for the killing of hiv-infected cells |
US5283187A (en) | 1987-11-17 | 1994-02-01 | Brown University Research Foundation | Cell culture-containing tubular capsule produced by co-extrusion |
US4892538A (en) | 1987-11-17 | 1990-01-09 | Brown University Research Foundation | In vivo delivery of neurotransmitters by implanted, encapsulated cells |
WO1989008114A1 (en) | 1988-02-25 | 1989-09-08 | The General Hospital Corporation | Rapid immunoselection cloning method |
US5506126A (en) * | 1988-02-25 | 1996-04-09 | The General Hospital Corporation | Rapid immunoselection cloning method |
IL85746A (en) | 1988-03-15 | 1994-05-30 | Yeda Res & Dev | Preparations comprising t-lymphocyte cells treated with 8-methoxypsoralen or cell membranes separated therefrom for preventing or treating autoimmune diseases |
US4861579A (en) | 1988-03-17 | 1989-08-29 | American Cyanamid Company | Suppression of B-lymphocytes in mammals by administration of anti-B-lymphocyte antibodies |
FI891226A (fi) | 1988-04-28 | 1989-10-29 | Univ Leland Stanford Junior | Reseptordeterminanter i anti-t-celler foer behandling av autoimmunsjukdom. |
GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
US5175384A (en) | 1988-12-05 | 1992-12-29 | Genpharm International | Transgenic mice depleted in mature t-cells and methods for making transgenic mice |
WO1990008187A1 (en) | 1989-01-19 | 1990-07-26 | Dana Farber Cancer Institute | Soluble two domain cd2 protein |
DE69006018T3 (de) | 1989-03-21 | 2004-01-15 | Immune Response Corp Inc | Impfung und methoden gegen krankheiten, die von pathologischen reaktionen der spezifischen t-zellen abstammen. |
DE3920358A1 (de) | 1989-06-22 | 1991-01-17 | Behringwerke Ag | Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung |
DE69029036T2 (de) | 1989-06-29 | 1997-05-22 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
DK0552142T3 (da) | 1989-07-19 | 1998-09-07 | Connetics Corp | T-cellereceptorpeptider og terapeutika til autoimmune og maligne sygdomme |
US5013556A (en) | 1989-10-20 | 1991-05-07 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
US5208020A (en) | 1989-10-25 | 1993-05-04 | Immunogen Inc. | Cytotoxic agents comprising maytansinoids and their therapeutic use |
US5229275A (en) | 1990-04-26 | 1993-07-20 | Akzo N.V. | In-vitro method for producing antigen-specific human monoclonal antibodies |
US5571894A (en) | 1991-02-05 | 1996-11-05 | Ciba-Geigy Corporation | Recombinant antibodies specific for a growth factor receptor |
EP0586505A1 (en) | 1991-05-14 | 1994-03-16 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
ES2206447T3 (es) * | 1991-06-14 | 2004-05-16 | Genentech, Inc. | Anticuerpo humanizado para heregulina. |
IE922437A1 (en) | 1991-07-25 | 1993-01-27 | Idec Pharma Corp | Recombinant antibodies for human therapy |
ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
US5587458A (en) | 1991-10-07 | 1996-12-24 | Aronex Pharmaceuticals, Inc. | Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof |
WO1993008829A1 (en) | 1991-11-04 | 1993-05-13 | The Regents Of The University Of California | Compositions that mediate killing of hiv-infected cells |
JPH07501451A (ja) | 1991-11-25 | 1995-02-16 | エンゾン・インコーポレイテッド | 多価抗原結合タンパク質 |
AU675929B2 (en) | 1992-02-06 | 1997-02-27 | Curis, Inc. | Biosynthetic binding protein for cancer marker |
ATE244763T1 (de) | 1992-02-11 | 2003-07-15 | Cell Genesys Inc | Erzielen von homozygotem durch zielgerichtete genetische ereignisse |
US5573905A (en) | 1992-03-30 | 1996-11-12 | The Scripps Research Institute | Encoded combinatorial chemical libraries |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
IL105914A0 (en) | 1992-06-04 | 1993-10-20 | Univ California | Methods and compositions for in vivo gene therapy |
DE4225853A1 (de) * | 1992-08-05 | 1994-02-10 | Behringwerke Ag | Granulozytenbindende Antikörperfragmente, ihre Herstellung und Verwendung |
ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
CA2149329C (en) | 1992-11-13 | 2008-07-15 | Darrell R. Anderson | Therapeutic application of chimeric and radiolabeled antibodies to human b lymphocyte restricted differentiation antigen for treatment of b cell lymphoma |
US5736137A (en) | 1992-11-13 | 1998-04-07 | Idec Pharmaceuticals Corporation | Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma |
US5417972A (en) | 1993-08-02 | 1995-05-23 | The Board Of Trustees Of The Leland Stanford Junior University | Method of killing B-cells in a complement independent and an ADCC independent manner using antibodies which specifically bind CDIM |
US5595721A (en) | 1993-09-16 | 1997-01-21 | Coulter Pharmaceutical, Inc. | Radioimmunotherapy of lymphoma using anti-CD20 |
GB9413127D0 (en) | 1994-06-30 | 1994-08-24 | Philips Electronics Uk Ltd | Data processing apparatus |
US5910486A (en) | 1994-09-06 | 1999-06-08 | Uab Research Foundation | Methods for modulating protein function in cells using, intracellular antibody homologues |
PT788513E (pt) * | 1994-10-25 | 2001-06-29 | Glaxo Group Ltd | Utilizacao de agentes de ligacao a cd23 no tratamento de doencas autoimunes |
US6214388B1 (en) | 1994-11-09 | 2001-04-10 | The Regents Of The University Of California | Immunoliposomes that optimize internalization into target cells |
US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
US5641870A (en) | 1995-04-20 | 1997-06-24 | Genentech, Inc. | Low pH hydrophobic interaction chromatography for antibody purification |
US5739277A (en) | 1995-04-14 | 1998-04-14 | Genentech Inc. | Altered polypeptides with increased half-life |
US5677189A (en) * | 1995-06-29 | 1997-10-14 | Oncomembrane, Inc. | Method for quantifying sphingosine and for diagnosing platelet activation |
JPH11510170A (ja) | 1995-07-27 | 1999-09-07 | ジェネンテック インコーポレーテッド | タンパク質の処方 |
ATE427353T1 (de) | 1997-02-10 | 2009-04-15 | Genentech Inc | Heregulin varianten |
US6306393B1 (en) | 1997-03-24 | 2001-10-23 | Immunomedics, Inc. | Immunotherapy of B-cell malignancies using anti-CD22 antibodies |
US6171586B1 (en) | 1997-06-13 | 2001-01-09 | Genentech, Inc. | Antibody formulation |
EP0999853B1 (en) | 1997-06-13 | 2003-01-02 | Genentech, Inc. | Stabilized antibody formulation |
DE69830315T2 (de) | 1997-06-24 | 2006-02-02 | Genentech Inc., San Francisco | Galactosylierte glykoproteine enthaltende zusammensetzungen und verfahren zur deren herstellung |
US6368596B1 (en) | 1997-07-08 | 2002-04-09 | Board Of Regents, The University Of Texas System | Compositions and methods for homoconjugates of antibodies which induce growth arrest or apoptosis of tumor cells |
ATE419009T1 (de) | 1997-10-31 | 2009-01-15 | Genentech Inc | Methoden und zusammensetzungen bestehend aus glykoprotein-glykoformen |
ATE375365T1 (de) | 1998-04-02 | 2007-10-15 | Genentech Inc | Antikörper varianten und fragmente davon |
US6528624B1 (en) * | 1998-04-02 | 2003-03-04 | Genentech, Inc. | Polypeptide variants |
US6194551B1 (en) | 1998-04-02 | 2001-02-27 | Genentech, Inc. | Polypeptide variants |
US6242195B1 (en) | 1998-04-02 | 2001-06-05 | Genentech, Inc. | Methods for determining binding of an analyte to a receptor |
EP1112084B2 (en) | 1998-08-11 | 2012-04-25 | Biogen Idec Inc. | Combination therapies for b-cell lymphomas comprising administration of anti-cd20 antibody |
US6224866B1 (en) | 1998-10-07 | 2001-05-01 | Biocrystal Ltd. | Immunotherapy of B cell involvement in progression of solid, nonlymphoid tumors |
WO2000027428A1 (en) | 1998-11-09 | 2000-05-18 | Idec Pharmaceuticals Corporation | Treatment of hematologic malignancies associated with circulating tumor cells using chimeric anti-cd20 antibody |
MY155913A (en) | 1998-11-09 | 2015-12-15 | Biogen Inc | Chimeric anti-cd20 antibody treatment of patients receiving bmt or pbsc transpants |
HUP0104865A3 (en) | 1999-01-15 | 2004-07-28 | Genentech Inc | Polypeptide variants with altered effector function |
US6897044B1 (en) | 1999-01-28 | 2005-05-24 | Biogen Idec, Inc. | Production of tetravalent antibodies |
US6383276B1 (en) * | 1999-03-12 | 2002-05-07 | Fuji Photo Film Co., Ltd. | Azomethine compound and oily magenta ink |
WO2000067796A1 (en) * | 1999-05-07 | 2000-11-16 | Genentech, Inc. | Treatment of autoimmune diseases with antagonists which bind to b cell surface markers |
US7074403B1 (en) | 1999-06-09 | 2006-07-11 | Immunomedics, Inc. | Immunotherapy of autoimmune disorders using antibodies which target B-cells |
ITMI991299A1 (it) | 1999-06-11 | 2000-12-11 | Consiglio Nazionale Ricerche | Uso di anticorpi contro antigeni di superficie per il trattamento della malattia trapianto contro ospite |
DE19930748C2 (de) * | 1999-07-02 | 2001-05-17 | Infineon Technologies Ag | Verfahren zur Herstellung von EEPROM- und DRAM-Grabenspeicherzellbereichen auf einem Chip |
JP2003528805A (ja) | 1999-07-12 | 2003-09-30 | ジェネンテック・インコーポレーテッド | Cd20に結合するアンタゴニストを用いた異種抗原に対する免疫応答のブロッキング |
US8557244B1 (en) | 1999-08-11 | 2013-10-15 | Biogen Idec Inc. | Treatment of aggressive non-Hodgkins lymphoma with anti-CD20 antibody |
CN100389825C (zh) | 1999-08-11 | 2008-05-28 | 拜奥根Idec公司 | 用抗cd20抗体治疗累及骨髓的非霍奇金淋巴瘤患者 |
US6451284B1 (en) | 1999-08-11 | 2002-09-17 | Idec Pharmaceuticals Corporation | Clinical parameters for determining hematologic toxicity prior to radioimmunotheraphy |
JP2001058956A (ja) * | 1999-08-19 | 2001-03-06 | Welfide Corp | 自己免疫疾患予防・治療剤 |
WO2001013945A1 (en) | 1999-08-23 | 2001-03-01 | Biocrystal Ltd. | Methods and compositions for immunotherapy of b cell involvement in promotion of a disease condition comprising multiple sclerosis |
US20020006404A1 (en) | 1999-11-08 | 2002-01-17 | Idec Pharmaceuticals Corporation | Treatment of cell malignancies using combination of B cell depleting antibody and immune modulating antibody related applications |
CA2404390A1 (en) | 2000-03-24 | 2001-10-04 | Chiron Corporation | Methods of therapy for non-hodgkin's lymphoma using a combination of an antibody to cd20 and interleukin-2 |
KR20020091170A (ko) * | 2000-03-31 | 2002-12-05 | 아이덱 파마슈티칼즈 코포레이션 | B 세포 림프종의 치료를 위한 항-사이토카인 항체 또는길항제 및 항-cd20의 조합된 사용 |
ES2528794T3 (es) | 2000-04-11 | 2015-02-12 | Genentech, Inc. | Anticuerpos multivalentes y usos de los mismos |
CN1437478A (zh) | 2000-04-25 | 2003-08-20 | Idec药物公司 | 瑞图希单抗的鞘内施用,用于中枢神经***淋巴瘤的治疗 |
WO2001097858A2 (en) | 2000-06-20 | 2001-12-27 | Idec Pharmaceuticals Corporation | Cold anti-cd20 antibody/radiolabeled anti-cd22 antibody combination |
WO2001097843A2 (en) | 2000-06-22 | 2001-12-27 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
JP2004502742A (ja) | 2000-07-12 | 2004-01-29 | アイデック ファーマスーティカルズ コーポレイション | B細胞を消滅させる抗体及び免疫調節抗体を併用するb細胞悪性疾患の治療関連出願 |
AU2002213357A1 (en) | 2000-10-20 | 2002-05-06 | Idec Pharmaceuticals Corporation | Variant igg3 rituxan r and therapeutic use thereof |
WO2002096948A2 (en) | 2001-01-29 | 2002-12-05 | Idec Pharmaceuticals Corporation | Engineered tetravalent antibodies and methods of use |
WO2002060955A2 (en) | 2001-01-29 | 2002-08-08 | Idec Pharmaceuticals Corporation | Modified antibodies and methods of use |
US20030003097A1 (en) | 2001-04-02 | 2003-01-02 | Idec Pharmaceutical Corporation | Recombinant antibodies coexpressed with GnTIII |
DE60239931D1 (de) | 2001-04-02 | 2011-06-16 | Genentech Inc | Kombinationstherapie |
JP2005515161A (ja) | 2001-06-14 | 2005-05-26 | インターミューン インコーポレイテッド | γ−インターフェロンおよびB細胞特異的抗体の併用療法 |
WO2003029296A1 (en) | 2001-10-02 | 2003-04-10 | Chiron Corporation | Human anti-cd40 antibodies |
CA2476166C (en) | 2002-02-14 | 2011-11-15 | Immunomedics, Inc. | Anti-cd20 antibodies and fusion proteins thereof and methods of use |
US7569673B2 (en) | 2002-06-28 | 2009-08-04 | The United States Of America As Represented By The Department Of Health And Human Services | Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors |
DE60332957D1 (de) * | 2002-12-16 | 2010-07-22 | Genentech Inc | Immunoglobulinvarianten und deren verwendungen |
ES2322267T3 (es) * | 2003-04-09 | 2009-06-18 | Genentech, Inc. | Terapia de una enfermedad autoinmunologica en un paciente que presenta una respuesta inadecuada a un inhibidor de tnf-alfa. |
MY149159A (en) * | 2005-11-15 | 2013-07-31 | Hoffmann La Roche | Method for treating joint damage |
-
2004
- 2004-04-06 ES ES04759142T patent/ES2322267T3/es not_active Expired - Lifetime
- 2004-04-06 KR KR1020117008598A patent/KR20110044809A/ko not_active Application Discontinuation
- 2004-04-06 KR KR1020057019095A patent/KR101092171B1/ko active IP Right Review Request
- 2004-04-06 MX MXPA05010778A patent/MXPA05010778A/es active IP Right Grant
- 2004-04-06 CN CNA2008101656563A patent/CN101371924A/zh active Pending
- 2004-04-06 ZA ZA200507805A patent/ZA200507805B/en unknown
- 2004-04-06 WO PCT/US2004/010509 patent/WO2004091657A2/en active Application Filing
- 2004-04-06 EP EP09002405A patent/EP2062916A3/en not_active Withdrawn
- 2004-04-06 JP JP2006509724A patent/JP2006522811A/ja not_active Withdrawn
- 2004-04-06 SI SI200431115T patent/SI1613350T1/sl unknown
- 2004-04-06 RU RU2005134394/14A patent/RU2358762C9/ru not_active IP Right Cessation
- 2004-04-06 BR BRPI0409534-0A patent/BRPI0409534A/pt not_active Application Discontinuation
- 2004-04-06 PT PT04759142T patent/PT1613350E/pt unknown
- 2004-04-06 UA UAA200510467A patent/UA91961C2/ru unknown
- 2004-04-06 UA UAA201006218A patent/UA99933C2/ru unknown
- 2004-04-06 AU AU2004229376A patent/AU2004229376B2/en not_active Expired
- 2004-04-06 US US10/818,765 patent/US20040202658A1/en not_active Abandoned
- 2004-04-06 CN CNA2004800161012A patent/CN1802176A/zh active Pending
- 2004-04-06 AT AT04759142T patent/ATE425766T1/de active
- 2004-04-06 DK DK04759142T patent/DK1613350T3/da active
- 2004-04-06 DE DE602004020061T patent/DE602004020061D1/de not_active Expired - Lifetime
- 2004-04-06 ME MEP-2008-636A patent/ME00426B/me unknown
- 2004-04-06 CA CA002519870A patent/CA2519870A1/en not_active Withdrawn
- 2004-04-06 RS YU20050761A patent/RS51686B/sr unknown
- 2004-04-06 PL PL04759142T patent/PL1613350T3/pl unknown
- 2004-04-06 EP EP04759142A patent/EP1613350B1/en not_active Revoked
- 2004-04-06 NZ NZ587776A patent/NZ587776A/en unknown
-
2005
- 2005-09-22 IL IL171038A patent/IL171038A/en active IP Right Grant
- 2005-09-23 TN TNP2005000234A patent/TNSN05234A1/en unknown
- 2005-10-06 CR CR8033A patent/CR8033A/es not_active Application Discontinuation
- 2005-10-07 EC EC2005006082A patent/ECSP056082A/es unknown
- 2005-11-03 HR HR20050940A patent/HRP20050940A2/hr not_active Application Discontinuation
- 2005-11-08 NO NO20055253A patent/NO20055253L/no unknown
- 2005-11-09 MA MA28595A patent/MA27838A1/fr unknown
-
2006
- 2006-05-24 US US11/439,906 patent/US7708994B2/en active Active
- 2006-06-06 HK HK06106467.5A patent/HK1086480A1/xx not_active IP Right Cessation
-
2008
- 2008-03-20 US US12/052,606 patent/US7976838B2/en active Active
-
2009
- 2009-06-02 HR HR20090325T patent/HRP20090325T1/xx unknown
- 2009-06-04 CY CY20091100598T patent/CY1109127T1/el unknown
- 2009-10-01 NZ NZ580116A patent/NZ580116A/en unknown
- 2009-10-13 JP JP2009235927A patent/JP2010047586A/ja not_active Withdrawn
- 2009-12-29 IL IL203019A patent/IL203019A/en active IP Right Grant
-
2011
- 2011-05-16 US US13/108,134 patent/US20110300136A1/en not_active Abandoned
-
2013
- 2013-03-01 JP JP2013040359A patent/JP5746243B2/ja not_active Expired - Lifetime
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RU2005134394A (ru) | Лечение аутоиммунных заболеваний у пациента с неадекватным ответом на ингибитор tnf-альфа | |
JP2022105084A5 (ru) | ||
ES2649155T3 (es) | Anticuerpos anti-OX40 y procedimientos de uso de los mismos | |
JP2019522680A5 (ru) | ||
JP2020501583A5 (ru) | ||
JP2014520092A5 (ru) | ||
Scadden et al. | Polyoma virus nephropathy in kidney transplantation | |
JP2011523351A5 (ru) | ||
JP2017501725A5 (ru) | ||
RU2007142523A (ru) | Способы лечения фиброзных состояний | |
Vogt et al. | Human antibodies neutralize enterovirus D68 and protect against infection and paralytic disease | |
MX2007014497A (es) | Pretratamiento de una muestra biologica de un sujeto con enfermedad autoinmune. | |
CN107266571A (zh) | 抗‑mcam抗体及相关使用方法 | |
EP3311171A1 (en) | Antibody epitope | |
JP6113279B2 (ja) | B型肝炎突然変異ウイルス感染の予防又は治療用抗体組成物 | |
KR102528090B1 (ko) | 트롬빈 안티트롬빈 복합체의 측정 시약 및 측정 방법 | |
Dunfee et al. | Enhanced macrophage tropism of HIV in brain and lymphoid tissues is associated with sensitivity to the broadly neutralizing CD4 binding site antibody b12 | |
Dendle et al. | Disseminated enteroviral infection associated with obinutuzumab | |
Carl et al. | Simian immunodeficiency virus containing mutations in N-terminal tyrosine residues and in the PxxP motif in Nef replicates efficiently in rhesus macaques | |
WO2009109584A1 (en) | ANTIBODY BINDING ONLY TO IL6-sIL6R COMPLEX | |
EP2892926A2 (en) | Compositions and methods | |
JPH0528598B2 (ru) | ||
Perez et al. | Lack of transmission of human immunodeficiency virus in chronic hemodialysis patients | |
WO2006106976A1 (ja) | 細胞膜表面抗原に対する抗体のアッセイ法 | |
McKERNAN et al. | Molecular size of the 5-HT3 receptor solubilized from NCB 20 cells |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
QB4A | Licence on use of patent |
Free format text: LICENCE Effective date: 20120907 |
|
TH4A | Reissue of patent specification | ||
MF41 | Cancelling an invention patent (total invalidation of the patent) |
Effective date: 20171226 |